KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

AbCellera Biologics (ABCL) Other Gross PP&E Adjustments (2020 - 2025)

AbCellera Biologics' Other Gross PP&E Adjustments history spans 6 years, with the latest figure at $223.4 million for Q3 2025.

  • For the quarter ending Q3 2025, Other Gross PP&E Adjustments fell 21.97% year-over-year to $223.4 million, compared with a TTM value of $223.4 million through Sep 2025, down 21.97%, and an annual FY2024 reading of $210.3 million, up 36.41% over the prior year.
  • Other Gross PP&E Adjustments for Q3 2025 was $223.4 million at AbCellera Biologics, up from $219.6 million in the prior quarter.
  • The five-year high for Other Gross PP&E Adjustments was $304.7 million in Q1 2025, with the low at $31.0 million in Q1 2021.
  • Average Other Gross PP&E Adjustments over 5 years is $181.6 million, with a median of $210.3 million recorded in 2024.
  • Year-over-year, Other Gross PP&E Adjustments soared 332.35% in 2021 and then dropped 21.97% in 2025.
  • Tracing ABCL's Other Gross PP&E Adjustments over 5 years: stood at $101.6 million in 2021, then surged by 52.39% to $154.9 million in 2022, then decreased by 0.47% to $154.2 million in 2023, then skyrocketed by 36.41% to $210.3 million in 2024, then grew by 6.22% to $223.4 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Other Gross PP&E Adjustments are $223.4 million (Q3 2025), $219.6 million (Q2 2025), and $304.7 million (Q1 2025).